MDWD - Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
For a year, Vericel (VCEL) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for "commercial products or businesses which would be... complementary to Vericel's existing commercial franchises or its advanced cell therapy platform..." And then, the wait began.
I wrote an article that June, speculating on acquisition targets and boldly asserting in Victorian era diction that a product acquisition was "nigh," and then a